SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
RIGL reported Q3 2026 results. The price and volatility reaction is pending.
RIGLearnings

Earnings reactions, page 5

Rigel Pharmaceuticals, Inc. (RIGL) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Third quarter 2026 total revenues were $80.9 million, consisting of $72.3 million in net product sales and $8.6 million in contract revenues from collaborations.
  • Third quarter 2026 net product sales were $72.3 million, representing an increase of 13% from the same period of 2025.
  • Rigel reported net income of $13.2 million, or $0.70 basic and $0.65 diluted per share, for the third quarter of 2026.
  • VEPPANU generated $6.6 million in initial net product sales for the third quarter of 2026.
  • Cash, cash equivalents and short-term investments as of September 30, 2026 were $99.3 million, compared to $155.0 million as of December 31, 2025.

Guidance

  • Total revenues of approximately $290 to $295 million
  • Net product sales, excluding VEPPANU, of $255 to $260 million
  • Contract revenues from collaborations of approximately $35 million

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →